• Zhihui Zhou, Wenjiang Zheng, Ting Liang, Qian Yan, Chaoyuan Zhang, Huiting Huang, Xiaohong Liu, and Xiaohan Ye.
• Dongguan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Dongguan.
• Medicine (Baltimore). 2020 Jan 1; 99 (2): e18620e18620.

BackgroundChuankezhi injection (CKZ) is gaining increasing popularity for chronic obstructive pulmonary disease (COPD) treatment, yet their comparative effectiveness and safety remain unclear. Therefore, we will provide a protocol to assess the efficacy and safety of CKZ for COPD.MethodsFrom now until June 2020, we will conduct a comprehensive and systematic literature search in 4 Chinese and 4 English databases, and the use of CKZ in the treatment of COPD will be included in randomized controlled trials, as well as all the treatment of stable COPD during the treatment of all CKZ. The risk assessment of the bias tool in Cochrane 5.1.0 will be combined with the quality of the trial. The 2 investigators will independently perform quality assessments and data extractions for the included studies in strict accordance with inclusion and exclusion criteria and perform the meta-analysis with Stata 15 software (version 15.0, StataCorp, College Station, TX).ResultsFurther evidence of CKZ treatment for COPD will be provided by this study.ConclusionThe efficacy and safety assessment of CKZ for COPD will be supported by this protocol.Prospero Registration NumberROSPERO CRD 42019134133.

15 keywords...

hide…